Doxorubicin Market Size

  • Report ID: 4876
  • Published Date: Oct 14, 2024
  • Report Format: PDF, PPT

Doxorubicin Market Size

Doxorubicin Market size was valued at USD 1.01 billion in 2024 and is set to reach USD 2.24 billion by the end of 2037, expanding at around 6.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of doxorubicin is assessed at USD 1.07 billion. The growth of the market can be attributed to the increasing prevalence of cancer worldwide along with the significant investments in research and development of doxorubicin. The World Health Organization reported that cancer caused nearly 10 million deaths worldwide in 2020. In 2020, breast cancer accounted for 2.26 million cases, lung cancer was 2.21 million, colon and rectal cancer was 1.93 million, prostate cancer was 1.41 million, skin cancer was 1.20 million, and stomach cancer was 1.09 million. As the number of people diagnosed with cancer continues to rise, there is a higher demand for treatments such as doxorubicin, which is an effective form of chemotherapy. Doxorubicin is an anti-cancer drug that works by targeting and destroying cancer cells while leaving healthy cells intact.

In addition to these, factors that are believed to fuel the market growth of doxorubicin include increasing penetration of doxorubicin in emerging countries, the growing number of clinical trials, and increasing investments in oncology research. Moreover, the rise in the number of people suffering from leukemia, a type of cancer affecting the blood and bone marrow is expected to drive market growth. In 2023, the American Cancer Society estimates about 59,610 new cases of leukemia (all types) and 23,710 deaths associated with leukemia will be reported, as well as approximately 20,380 new cases of acute myeloid leukemia (AML) registered. Doxorubicin is used to treat a variety of blood cancers, such as acute myeloid leukemia and Hodgkin's lymphoma. It works by disrupting the production of proteins that cancer cells need to survive.


Doxorubicin Market Overview
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4876
  • Published Date: Oct 14, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of doxorubicin is assessed at USD 1.07 billion.

The doxorubicin market size was valued at USD 1.01 billion in 2024 and is set to reach USD 2.24 billion by the end of 2037, expanding at around 6.9% CAGR during the forecast period i.e., between 2025-2037. Increasing prevalence of cancer and rising demand for targeted therapies will boost the market growth.

North America industry is projected to have the highest growth till 2037, owing to increasing investments in research and development for new treatments for breast cancer in the region.

The major players in the market include Pfizer Inc., Johnson and Johnson, Zydus Group, Cipla Limited, Sun Pharmaceutical Industries Ltd, Padagis, Reddy Laboratories Ltd., Cadila Healthcare Limited, Novartis International AG, MicroBiopharm Japan Co. Ltd, .
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample